세계 말초 삽입형 중심정맥 카테터(PICC) 디바이스 시장 규모는 2023년 9억 7,613만 달러, 2030년에는 13억 2,659만 달러에 달할 것으로 예상되며, 2024-2030년의 예측 기간 동안 5.29%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다. 말초 삽입형 중심정맥 카테터(PICC) 디바이스 수요는 주로 암 및 감염과 같은 질병 발병률 증가, 특히 제품 포트폴리오의 기술 발전, 제품 출시 증가 및 적절한 상환 등의 요인에 의해 촉진되고 있으며, 따라서 2024-2030년의 예측 기간 동안 말초 삽입형 중심정맥 카테터(PICC) 중심정맥카테터(PICC) 디바이스 시장에 긍정적인 시장 성장을 창출할 것으로 예상됩니다.
말초 삽입형 중심정맥 카테터(PICC) 시장 역학
암, 감염성 질환의 지속적인 증가는 말초 삽입형 중심정맥 카테터(PICC) 시장의 성장을 가속하고 있습니다. 예를 들어, 국제암연구소(International Agency for Research on Cancer)의 조사에 따르면 2020년 전 세계적으로 1,930만 건의 새로운 암 사례가 보고된 것으로 추정됩니다.
세계보건기구(WHO)(2022)의 데이터에 따르면 2020년 전 세계적으로 유방암 226만 건, 폐암 221만 건, 대장암 193만 건, 전립선암 141만 건, 위암 109만 건이 보고됐습니다.
또한, Global Cancer Observatory(2021) 자료에 따르면, 2020년 전 세계적으로 약 54만 4,352건의 비호지킨림프종과 8만 3,087건의 호지킨림프종이 보고됐습니다. 이 자료에 따르면, 2020년 전 세계적으로 약 47만 4,519건의 백혈병과 약 17만 6,404건의 다발성 골수종이 보고됐습니다.
Global Cancer Observatory(2023)가 발표한 자료에 따르면, 2020년 전 세계적으로 약 141만 건의 전립선암이 새로 발생했으며, 2040년까지 이 수치는 224만 건에 달할 것으로 예측됩니다.
세계보건기구(WHO)(2022)에 따르면 2020년 전 세계적으로 약 3,770만 명이 인간면역결핍바이러스(HIV)에 감염된 것으로 나타났습니다. 또한 유럽질병예방통제센터(ECDC)(2021)에 따르면 지난 30년간 WHO 유럽지역에서 220만 명 이상이 HIV 진단을 받았으며, 2020년 유럽에서 약 10만 4,765명이 새로이 HIV 진단을 받았다고 보고했습니다.
PICC 장치는 감염 환자에게 항생제와 항진균제를 투여하는 데 사용됩니다. 미국 질병예방통제센터(CDC)가 2021년 발표한 자료에 따르면, 18세 이상 미국 성인의 47.8%가 2020-2021년 독감 예방접종을 받았다고 합니다.
그러나 PICC 기기 사용에 따른 합병증과 제품 리콜 증가는 말초 삽입형 중심정맥카테터(PICC) 기기 시장의 성장을 저해할 수 있습니다.
말초 삽입형 중심정맥 카테터(PICC) 디바이스 시장 부문 분석
말초 삽입형 중심정맥 카테터(PICC) 디바이스 시장의 설계 부문에서 트리플 루멘 카테고리는 2023년 52.26%의 매출 점유율을 차지했습니다. 이는 트리플 루멘 말초 삽입형 중심정맥 카테터(PICC) 디바이스와 관련된 다양한 장점에 기인하는 것으로 보입니다.
트리플 루멘 PICC는 여러 가지 주입이 필요한 경우에 적합하며, 하나의 접근 부위에서 여러 가지 다른 주입을 할 수 있습니다. 각 채널에 별도의 주입이 가능합니다. 캐뉼라 원위부의 서로 다른 위치에 3개의 채널과 루멘이 있어 약물 주입, 채혈, 중심정맥압(CVP) 모니터링을 동시에 수행할 수 있습니다.
또한, 트리플 루멘 카테터는 3개의 주입 채널이 있어 여러 가지 치료제를 동시에 투여할 수 있어 중환자실에서 가장 선호되는 카테터입니다. 트리플 루멘 카테터는 식도암 환자에게 약물을 투여하고 필요한 수액을 주입하는 데 일상적으로 사용되고 있습니다.
세계 말초 삽입형 중심정맥 카테터(PICC) 디바이스 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 전해드립니다.
Peripherally Inserted Central Catheter (PICC) Devices Market By Product Type (Power Injected Peripherally Inserted Catheters, Non-Power Injected/ Conventional Peripherally Inserted Central Catheters), Design (Single Lumen, Double Lumen, Triple Lumen), End-User (Hospitals, Ambulatory Surgical Centers, And Others) and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing incidence of cancers and infectious diseases and the various technological advancements in product portfolio
The global Peripherally Inserted Central Catheter (PICC) Devices market was valued at USD 976.13 million in 2023, growing at a CAGR of 5.29% during the forecast period from 2024 to 2030 to reach USD 1,326.59 million by 2030. The demand for peripherally inserted central catheter devices is primarily being boosted owing to the key factors such as the increasing incidence of cancers, and infectious diseases, among others, technological advancements in product portfolio, and proper reimbursement coupled with increasing product launches, thus creating a positive market growth for the Peripherally Inserted Central Catheter (PICC) Devices market during the forecast period from 2024-2030.
Peripherally Inserted Central Catheter (PICC) Devices Market Dynamics:
The continuous rise in the cases of cancer, infectious, and other diseases is driving the growth of the peripherally inserted central catheter devices market. For instance, the study conducted by the International Agency for Research on Cancer mentioned that worldwide, an estimated number of 19.3 million new cancer cases were reported in 2020.
According to data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.
Also, as per the Global Cancer Observatory 2021 data, globally around 544,352 cases of Non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020. As per the same source globally around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020.
The data published by Global Cancer Observatory (2023) says that globally around 1.41 million new cases of prostate cancer were reported in 2020 and by 2040 this number is expected to reach 2.24 million.
According to World Health Organization (WHO) 2022, globally there were around 37.7 million people suffering from human immunodeficiency virus (HIV) in year 2020. Also, as per the European Centre for Disease Prevention and Control (ECDC) 2021, over the course of the last three decades, over 2.2 million people have been diagnosed and reported with HIV in the WHO European Region. In 2020, nearly 104,765 people were newly diagnosed with HIV in the European region.
PICC devices are employed in delivery of antibiotics and antifungal medicines in patients suffering from infectious diseases. According to the data cited in 2021 by Centers for Disease Control and Prevention, 47.8% percent of US adults aged 18 and over received an influenza vaccination in the 2020-2021 duration.
However, complications associated with the use of PICC devices and the increasing number of product recalls may restrict the growth of the peripherally inserted central catheter devices market.
Peripherally Inserted Central Catheter (PICC) Devices Market Segment Analysis:
Peripherally Inserted Central Catheter (PICC) Devices market By Product type (Power Injected Peripherally Inserted Catheters, Non-Power Injected/ Conventional Peripherally Inserted Central Catheters), Design (Single Lumen, Double Lumen, Triple Lumen), End-User (Hospitals, Ambulatory Surgical Centers, And Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the design segment of the peripherally inserted central catheter devices market, the triple lumen category held a revenue share of 52.26% in the year 2023. This can be ascribed to the various advantages associated with triple lumen peripherally inserted central catheter (PICC) devices.
Triple lumen PICC are suitable for use when multiple infusions are required to be performed. It allows to run several different infusion with only one access site. It offers separate infusion for each channel. It has three channels and lumens present at different positions on the distal cannula which provide ports for simultaneous drug infusion, blood drawing, and central venous pressure (CVP) monitoring.
Moreover, triple lumen catheters are most preferred ICU settings for their three infusion channels that allows for simultaneous administration of multiple therapies. Triple lumen catheters are routinely employed for the delivery of medications and other necessary fluids to patients with esophageal cancer.
In patients under intensive care and patients undergoing bone marrow transplants (BMT), triple lumen catheters are mostly preferred over other types. For example, Poly Per-Q-Cath3 by BD is an example of triple lumen catheter indicated for short or long term peripheral access to the central venous system for intravenous therapy and blood sampling.
Therefore, owing to the above-mentioned factors, the triple lumen category is expected to hold a respectable revenue share in the peripherally inserted central catheter (PICC) devices market during the forecast period.
North America is expected to dominate the overall Peripherally Inserted Central Catheter (PICC) Devices Market:
In the PICC devices global market, North America is expected to hold the largest share of 46.65% in the year 2023. Owing to the significance of key growth factors such as the increasing incidence of cancer, infectious, and other diseases, along with their risk factors, increasing healthcare expenditure, favorable reimbursement policies, rising research and development activities in the region including launches and approvals, among others, the market for peripherally inserted central catheter devices is expected to witness prosperity in the region during the forecast period from 2024-2030.
In the United States, the rising cases of chronic disorders such as cancers, respiratory disorders, gastrointestinal disorders in the region is likely to increase the demand for PICC.
For instance, according to the Centre for Disease Control and Prevention (CDC) 2020, Cystic fibrosis (CF), a genetic disorder that causes problems with breathing and digestion affects about 35,000 people in the United States, every year on an average.
In addition, people suffering from cystic fibrosis who need intravenous (IV) antibiotic treatments is for more than just a few days, such as during an exacerbation, which could potentially raise the demand for PICC catheters.
The Public Health Agency of Canada (2023) report stated that in 2020, the rate of active tuberculosis in Canada was 4.7 per 100,000 population. The peripherally inserted central catheters (PICCs) are frequently used to deliver intravenous antimicrobial therapy. Thus, the increasing prevalence of such infections in the country will propel the demand for PICC devices. Canada Institute for Health Information (CIHI) 2023, in 2021-2022, there were almost 2.9 million acute inpatient hospitalizations in Canada, up from 2.7 million visits in 2020-2021. The rising figures of hospitalizations in the country will increase the demand for PICC devices as these devices will be used to administer medications, fluids, and blood products to the hospitalized patients.
Thus, the interplay of all the above-mentioned factors would potentially help in driving the North America Peripherally Inserted Central Catheter (PICC) Devices market forward during the forecast period.
Peripherally Inserted Central Catheter (PICC) Devices Market Key Players:
Some of the key market players operating in the Peripherally Inserted Central Catheter (PICC) Devices market include B. Braun Melsungen AG, AngioDynamics, Cardinal Health, BD, Teleflex Incorporated, Argon Medical, Cook Group, ICU Medical Inc., Medical Components Inc., Access Vascular, Vygon, Meditech Devices, Biowy Corporation, Polymedicure, Footprint Medical Inc., SILMAG GROUP, pfm medical ag, Healthline Medical Products, INSUNG MEDICAL Co., Ltd., Equipos de Biomedicina de Mexico, S.A. de C.V, and others.
Recent Developmental Activities in the Peripherally Inserted Central Catheter (PICC) Devices Market:
In May 2022, Access Vascular, Inc., received the US FDA 510(k) clearance for its HydroPICC® Dual-Lumen catheter which has been designed and constructed using the same proprietary hydrophilic biomaterial as AVI's single-lumen HydroPICC® and HydroMID® catheters, with the aim to reduce complications such as occlusions, replacements, Deep Vein Thrombosis and phlebitis associated with use of multiple lumen catheters.
In March 2020, Biowy PICC-S kit received 510(k) clearance from the US FDA.
In March 2020, Access Vascular, Inc. received FDA clearance for the second generation of its HydroPICC, which demonstrated an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter.
Key Takeaways from the Peripherally Inserted Central Catheter (PICC) Devices Market Report Study
Market size analysis for current Peripherally Inserted Central Catheter (PICC) Devices market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Peripherally Inserted Central Catheter (PICC) Devices market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global Peripherally Inserted Central Catheter (PICC) Devices market.
Various opportunities available for the other competitor in the Peripherally Inserted Central Catheter (PICC) Devices market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current Peripherally Inserted Central Catheter (PICC) Devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Peripherally Inserted Central Catheter (PICC) Devices market growth in the coming future?
Target Audience who can be benefited from this Peripherally Inserted Central Catheter (PICC) Devices Market Report Study
Peripherally Inserted Central Catheter (PICC) Devices products providers
Research organizations and consulting companies
Peripherally Inserted Central Catheter (PICC) Devices -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in Peripherally Inserted Central Catheter (PICC) Devices
Various End-users who want to know more about the Peripherally Inserted Central Catheter (PICC) Devices market and the latest technological developments in the Peripherally Inserted Central Catheter (PICC) Devices market.
Frequently Asked Questions for the Peripherally Inserted Central Catheter (PICC) Devices Market:
Peripherally Inserted Central Catheter (PICC) device is a thin and flexible tube which is inserted into a vein to give intravenous fluids, blood transfusions, chemotherapy, and other drugs.
The global Peripherally Inserted Central Catheter (PICC) devices market was valued at USD 976.13 million in 2023, growing at a CAGR of 5.29% during the forecast period from 2024 to 2030 to reach USD 1,326.59 million by 2030.
The demand for Peripherally Inserted Central Catheter (PICC) devices is primarily being boosted owing to the key factors such as the increasing incidence of cancer, and infectious diseases, among other, technological advancement in the product portfolio, and proper reimbursement coupled with increasing product launches, thus creating a positive market growth of the Peripherally Inserted Central Catheter (PICC) Devices market during the forecast period from 2024-2030.
Some of the key market players operating in the Peripherally Inserted Central Catheter (PICC) devices include B. Braun Melsungen AG, AngioDynamics, Cardinal Health, BD, Teleflex Incorporated, Argon Medical, Cook Group, ICU Medical Inc., Medical Components Inc., Access Vascular, Vygon, Meditech Devices, Biowy Corporation, Polymedicure, Footprint Medical Inc., SILMAG GROUP, pfm medical ag, Healthline Medical Products, INSUNG MEDICAL Co., Ltd., Equipos de Biomedicina de Mexico, S.A. de C.V, and others.
North America is expected to dominate the overall Peripherally Inserted Central Catheter (PICC) Devices market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the increasing incidence of cancer, infectious, and other diseases, along with their risk factors, increasing healthcare expenditure, favourable reimbursement policies, rising research and development activities in the region including launches and approvals, among others, the market for peripherally inserted central catheter devices is expected to witness prosperity in the region during the forecast period from 2024-2030.